GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pulmatrix Inc (NAS:PULM) » Definitions » YoY Rev. per Sh. Growth
中文

Pulmatrix (Pulmatrix) YoY Rev. per Sh. Growth

: 28.57% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Pulmatrix's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 was 28.57%.

Pulmatrix's Revenue per Share for the three months ended in Dec. 2023 was $0.60.

Pulmatrix YoY Rev. per Sh. Growth Historical Data

The historical data trend for Pulmatrix's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmatrix Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,171.87 -7.03 -78.28 -7.70 13.46

Pulmatrix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 194.97 16.76 27.85 -10.78 28.57

Pulmatrix YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Pulmatrix's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(1.998-1.761)/ | 1.761 |
=13.46 %

Pulmatrix's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2023 )
=(Revenue per Share (Q: Dec. 2023 )-Revenue per Share (Q: Dec. 2022 )) / | Revenue per Share (Q: Dec. 2022 )) |
=(0.603-0.469)/ | 0.469 |
=28.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulmatrix YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Pulmatrix's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmatrix (Pulmatrix) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pulmatrix Inc (NAS:PULM) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
BZYR KTRA CUBT TTNP BCLI JAGX BTTX THER CYCN PYPD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
2PU:Germany
Address
99 Hayden Avenue, Suite 390, Lexington, MA, USA, 02421
Website
https://www.pulmatrix.com
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
Executives
Peter Ludlum officer: Interim CFO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Margaret Wasilewski officer: Chief Medical Officer C/O PULMATRIX, INC., 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Anand Varadan director C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Todd Bazemore director C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Christopher Cabell director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Michelle Siegert officer: Vice President, Finance 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Richard P. Batycky director C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Nelsen other: Former 10% owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Polaris Venture Partners Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Entrepreneurs' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Special Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Management Co. V, L.l.c. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Jonathan A Flint 10 percent owner 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Polaris Venture Management Co Iv Llc 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210